In Janurary 2018，BTBP established the CNBG Blood Products R&D Center which integrated the R&D technologies and talents across the group and built a comprehensive blood product research and innovation system. It standardized and managed the entire chain of new product development, quality control, registration and application, and clinical trial operation, promoting the company's high-quality development through scientific research and innovation. In 2023, the 4th generation of 10% Intravenous Immunoglobulin (蓉生静丙® 10%) manufactured with chromatography process is the first in China approved for marketing, and the Recombinant Human Coagulation Factor VIII has also obtained the Marketing Authorization.